Connect with us
A recent study from the Università degli Studi di Milano in Italy, published in the Journal of Natural Products under the auspices of the American Chemical Society, reveals that...
Epilepsy, as a chronic neurological disease, affects a substantial number of individuals globally, with a significant subset of patients demonstrating an unsatisfactory response...
SOMAÍ Pharmaceuticals, a multinational operator with EU-GMP certification, through a partnership with Universidade Lusófona, has published a peer-reviewed study in the renowned journal...
A systematic review entitled “The differential effects of medicinal cannabis on mental health” carried out by researchers at Erasmus University Rotterdam in the Netherlands addresses the role...
Cannabidiol (CBD) may offer promising therapeutic benefits for conditions such as epilepsy and neurodegenerative diseases. Despite its great potential and being well...
There are over 209 million cannabis users worldwide and both recreational and medicinal users are increasingly curious about...
Hemp cultivation has been growing in popularity, thanks to its potential to produce cannabidiol (CBD) and fiber. Recent research from the University of...
The attempt to combat age-related cognitive decline through the use of cannabinoids is gaining more and more consistency. A preclinical study...
Cannabis, often criticized for its effects on short-term memory, may not have the negative impact on long-term brain health that it does...
The medical cannabis industry continues to evolve, with research paving the way for innovative therapeutic applications. SOMAÍ Pharmaceuticals, a leading multinational operator certified...
